InvestSMART

Dorsavi Ltd (ASX: DVL) - Share Price

Current share price for DVL : $0.026 0.001 (4%)+

DorsaVi Ltd (DVL), an ASX-listed company, is an ASX listed company developing motion analysis device technologies for clinical use, elite sports, and occupational health and safety. The entity states that its wearable sensor technology enables detailed aspects of human movement and position to be captured, quantified, and assessed outside a biomechanics laboratory in real time and in practical environments for periods of up to 24 hours.

DVL General Information +

ASX Code DVL
Website http://www.dorsavi.com
Industry/Sector Health Care Equipment
Market Cap ($M) 32
DVL Share Price $0.026
Day High $0.027
Day Low $0.025
Last Close $0.025
DVL Share Price Movement $0.00 ( 4% )
Prices as at 16:36, 22 Jul 2026
+Security prices are delayed by at least 20 minutes and are indicative only.

Dorsavi Ltd (DVL) Upcoming Dividends & Yields

Distribution Type Dividend Franking Ex-dividend date Payment date Current Price+ Price 7D Avg Dividend Yield

See all dividends from Dorsavi Ltd (DVL) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.

Dorsavi Ltd (DVL) price-sensitive announcements

DVL - dorsaVi Commences Tape-Out of Validation Chip
On July 15, 2026, dorsaVi Limited announced the commencement of the tape-out process for i
Dorsavi Ltd (DVL)
15 Jul 2026 | 8:33 AM
DVL - dorsaVi Finalises RRAM-CMOS Validation Chip Design
dorsaVi Limited (ASX: DVL) has finalized the design of its first integrated RRAM-CMOS vali
Dorsavi Ltd (DVL)
18 Jun 2026 | 9:04 AM
DVL - dorsaVi Well Funded Following $500k Options Exercise
dorsaVi Limited announced that it has successfully raised $500,000 through the exercise of
Dorsavi Ltd (DVL)
15 Jun 2026 | 9:52 AM
DVL - dorsaVi Licenses Human Robot Collaboration IP
dorsaVi Limited has announced the licensing of two significant robotics intellectual prope
Dorsavi Ltd (DVL)
10 Jun 2026 | 8:38 AM

Dorsavi Ltd (DVL) Recent ASX Announcements

Company Sector Market Cap ($m) Headline Release
date/time+
Price at
release+
Current
price+
Gain/Loss View
Dorsavi Ltd (DVL)
ORDINARY FULLY PAID
Health Care $32 dorsaVi Commences Tape-Out of Validation Chip 15 Jul 2026 8:33AM $0.026 $0.026 fallen by 0%
Dorsavi Ltd (DVL)
ORDINARY FULLY PAID
Health Care $32 Notification of cessation of securities - DVL 14 Jul 2026 4:30PM $0.026 $0.026 fallen by 0%
Dorsavi Ltd (DVL)
ORDINARY FULLY PAID
Health Care $32 dorsaVi Finalises RRAM-CMOS Validation Chip Design 18 Jun 2026 9:04AM $0.040 $0.026 fallen by 35%
Dorsavi Ltd (DVL)
ORDINARY FULLY PAID
Health Care $32 Section 708A Cleansing Notice 15 Jun 2026 5:47PM $0.041 $0.026 fallen by 36.59%
Dorsavi Ltd (DVL)
ORDINARY FULLY PAID
Health Care $32 Application for quotation of securities - DVL 15 Jun 2026 5:37PM $0.041 $0.026 fallen by 36.59%
Dorsavi Ltd (DVL)
ORDINARY FULLY PAID
Health Care $32 dorsaVi Well Funded Following $500k Options Exercise 15 Jun 2026 9:52AM $0.039 $0.026 fallen by 33.33%

DVL Financial Summary

Year to Jun NPAT EPS EPS chg (%) PER DPS Yield (%) Franking (%)
2025A -$1.52 -$0.20 -4.40% 0.00 0.00 0.00% 0.0%
2024A -$1.25 -$0.20 -41.00% 0.00 0.00 0.00% 0.0%
2023A -$1.82 -$0.40 -23.50% 0.00 0.00 0.00% 0.0%

DVL Peer Comparison

Company Mkt Cap EPS Growth (%) P/E (%) Dividend Yield (%)
2023 A 2024 A 2025 A 2023 A 2024 A 2025 A 2023 A 2024 A 2025 A
Cochlear Limited (COH) $7,782M 0.0171 -0.1894 0.0615 19.8854 24.5320 23.1099 3.61% 2.91% 3.03%
Dorsavi Ltd (DVL) $33M -0.0435 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%
Fisher & Paykel Healthcare Corporation Limited (FPH) $19,510M 0.1388 0.1362 0.1882 50.2344 44.2108 37.2088 1.31% 1.40% 1.58%
ResMed Inc. (RMD) $16,745M 0.3087 9.7669 0.0729 193.8790 18.0070 16.7828 1.19% 1.25% 1.31%

DVL Market Comparison

Earnings P/E Ratio P/B Ratio P/E Growth
Company 0.00 0.00 7.35 0.00
Market 0.31 12.80 1.12 0.58
Sector 0.69 20.50 1.54 1.88

DVL Directors

Name Position Start Date
Mr Leigh Daniel Travers Non-Executive Director 4 Dec 2024
Mr Vineet Agarwal Non-Executive Director 16 Sep 2024
Mr Gernot Kurt Abl Non-Executive Director, Non-Executive Chairman 13 Mar 2024

Dorsavi Ltd (DVL) Changes in Directors' Interest & Trades

Date of change Director Buy/Sell Security Type Qty Trade Price Value
15 Nov 2024 WINLO, Michael Issued Direct Shares 2,797,394 $0.012 $32,729.510
15 Nov 2024 RONCHI, Andrew Issued Indirect Shares 3,636,363 $0.011 $39,999.993
15 Nov 2024 ABL, Gernot Issued Indirect Shares 1,619,821 $0.012 $18,951.906

See all changes in directors' interest & trades for Dorsavi Ltd (DVL) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.

DVL Management

Name Position
Mathew Regan Chief Executive Officer
Justin Mouchacca Company Secretary

DVL Substantial Shareholders

Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Dorsavi Ltd (DVL). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.

Holding Name
91,075,928 (8.09%) Ifrah Nishat
58,994,271 (5.24%) Chunyan Niu

DVL Calendar of Events

Date Event
25 February 2027 Report (Interim)
28 September 2026 Report (Annual)
28 August 2026 Report (Prelim)

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.